explore -WSS

explore

author：knowledge 2025-09-28 23:31:19 - browse：14

At some point this summer, the drugmaker Novo Nordisk will release results from a closely watched study that, if successful, could further uncork demand for new obesity medications, streamline insurance coverage for the therapies, and demonstrate long-lasting health benefits.

The Select trial, as the study is called, is the first large, randomized trial to test whether long-term treatment with a weight loss drug can meaningfully improve patients’ cardiovascular health. Novo is testing Wegovy, a weekly injection also sold under the brand name Ozempic for type 2 diabetes, against placebo in the five-year study.

The implications are massive, and not just for Novo. Wegovy is part of a class of medicines that target a hormone called GLP-1, which curbs patients’ appetites. Those drugs have demonstrated an ability to help people lose dramatic amounts of weight in clinical trials, but payers, including Medicare, have been slow to reimburse for them without definitive data on their long-term health benefits.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： The health care issue Democrats can’t solve: hospital reform

knowledge

WSS

Judge denies Trump's request for new trial in E. Jean Carroll case

Sanders wants to replace patents with prizes for drug inventions

All of Us, NIH's precision medicine initiative, gets a big boost

Bill would allow buprenorphine prescription for addiction via telehealth

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

Live blog: Hearing on CRISPR

focus

explore

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

5 dead in mass shooting on Caribbean island of St. Vincent: Police

Medical records are filled with copy

Thousands of UK hospital doctors walk out in the latest pay dispute, crippling health services

Guidelines to prevent youth baseball injuries need more muscle

Kidney transplant patients stopped immunosuppressants in trial

Moonlake's readout produced a cash windfall. Risks remain

Are infertility treatments 'essential' during the Covid

Heart attack and stroke risk calculators need revising

US jobless claims fall again as labor market continues to flash strength

explore

How to convince healthy people to buy insurance

The health care issue Democrats can’t solve: hospital reform

After Sarepta trial failure, Duchenne families brace for more debate

Stanford president’s abrupt resignation sparks debate

Headers linked to memory issues, raising questions about soccer safety as the World Cup kicks off

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

explore

knowledge

knowledge

entertainment